Health Condition 1: E35- Disorders of endocrine glands in diseases classified elsewhere Health Condition 2: G89-G99- Other disorders of the nervous system
Conditions
Interventions
Control Intervention1: Group A
Group B: Group A: Patients will receive 1 mg/100 ml of adrenaline (1:100000) for instillation in the nostrils
Group B: Patients will receive 0.5mg/100ml of adrenaline (1
Sponsors
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: a. ASA I and II patients b. Patients with pituitary or sellar masses for which the surgery is indicated c. Either Gender d.Age 18 to 65 years
Exclusion criteria
Exclusion criteria: a.Unwilling or unable to give consent b.Decreased levels of conciousnes, raised intracranial pressure c.Recurrent pituitary tumour or pituitary apoplexy d.Patients with cardiac pathology or severe hypertension e.Previous nasal surgery f.History of allergy to drugs used g.Patients with body weight , 40 kg
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparision of cardiac indices (blood pressures, heart rate, cardiac output, cardiac index, stroke volume, stroke volume variations) in patients receiving two different concentration of adrenaline (1:100000 and 1:200000 dilution) in transphenoidal surgeryTimepoint: Comparision of cardiac indices (blood pressures, heart rate, cardiac output, cardiac index, strokevolume and stroke volume variations )which are recorded at every five minutes for the first one hour following which everythey are recorded at every ten minutes till the completion of the surgery | — |
Secondary
| Measure | Time frame |
|---|---|
| a.Comparision of volume of blood loss b.Surgical assessment of the surgical field using Boezaarts scale c.Adverse effects like hypertension, hypotension and arrythmiasTimepoint: During the entire course of the procedure | — |
Countries
India
Contacts
Public ContactRudrashish Haldar
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Outcome results
None listed